A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit

ALK: Starting in 2026, research and development investment will focus more on innovative drug projects

On October 29th, ALK stated during an institutional research that after 2-3 years of high-intensity R&D investment, the company's previously planned generic drug projects have gradually entered the output stage. Starting in 2026, R&D investment related to generic drugs is expected to gradually decrease, with more focus on innovative drug projects

ALK: Subsidiary obtains approval number for "Amoxicillin Clavulanate Potassium Tablets" veterinary drug product

ALK's subsidiary, Animal Health Technology, has obtained the approval number for the veterinary drug product "Amoxicillin Clavulanate Potassium Tablets" from the Ministry of Agriculture and Rural Affairs, with approval numbers 111183373 and 111183374, valid until October 23, 2030. This product is used to treat bacterial infections in dogs and cats, meets the conditions for market sales, will enrich the company's product line, and promote the strategic layout of pet medications, but there is uncertainty regarding its market launch

ALK released its performance for the first three quarters, with a net profit attributable to the parent company of 77.6899 million yuan, a year-on-year increase of 55.59%

According to the Zhitong Finance APP, ALK released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.055 billion yuan, a year-on-year decrease of 5.92%. The net profit attributable to shareholders of the listed company was 77.6899 million yuan, a year-on-year increase of 55.59%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 55.7652 million yuan, a year-on-year increase of 39.70%

The innovative drug concept strengthened at the beginning of the trading session, with MEDISAN and ALK both hitting the daily limit

The innovative drug concept strengthened at the beginning of the trading session, with MEDISAN and ALK both hitting the daily limit, followed by gains in Shutaishen, Asia-Pacific Pharmaceutical, Duoyi Pharmaceutical, Yipinhong, Shanghai Yizhong, and Jinshiya Pharmaceutical